Skip to main content
. Author manuscript; available in PMC: 2014 Jun 16.
Published in final edited form as: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005612. doi: 10.1002/14651858.CD005612.pub2

Pregabalin versus placebo: 50% seizure reduction - ITT for drug-resistant partial epilepsy.

Patient or population: patients with drug-resistant partial epilepsy
Settings:
Intervention: Pregabalin versus placebo: 50% seizure reduction - ITT
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI) 		No of Participants
(studies) 		Quality of the evidence
(GRADE) 		Comments
Assumed risk Corresponding risk
Control Pre-gabalin versus placebo: 50% seizure reduction - ITT
50% responders, ITT - any dose pregabalin 15 per 100 40 per 100
(26 to 61)		 RR 2.61
(1.7 to 4.01)		 1868
(6 studies)		 ⊕⊕⊕○
moderate 1,1
*

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval;

RR: Risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1

High heterogeneity statistic.

2

All studies sponsored by the same pharmaceutical company all reporting significant findings.